GOTHENBURG, Sweden, April 11, 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), today announced that the company’s annual report and corporate governance report for the financial year 2024 are now available, in Swedish as well as an English translation, on the company’s website, www.isofolmedical.com. The information in the press release is intended for investors. […]
GOTHENBURG, Sweden, April 3, 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces that the company’s Japanese development and commercialization partner, Solasia Pharma K.K., intends to invest approximately 140 MSEK in the upcoming phase II and III trials of arfolitixorin in Japan and a subsequent regulatory submission for the treatment of metastatic colorectal cancer.
GOTHENBURG, Sweden, March 17, 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that the company has expanded its network of advisors with Godefridus (Frits) J. Peters, a prominent expert on the pharmacology of anticancer treatments and key opinion leader (KOL) active at the Amsterdam University Medical Center and other institutions. The information
Isofol expands network of advisors with prominent expert Read More »
GOTHENBURG, Sweden, March 12, 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces that the company’s CEO will present the company and its drug candidate arfolitixorin at Stora Aktiedagarna in Stockholm today, Wednesday March 12. The information in the press release is intended for investors. Today, Wednesday, March 12, at 1:30-1:55 p.m., Petter Segelman
Isofol presents at Stora Aktiedagarna on March 12 Read More »
GOTHENBURG, Sweden, March 5, 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces that the company will participate in several investor and partnering meetings during the spring, to present the company and its drug candidate arfolitixorin. The information in the press release is intended for investors. Isofol’s CEO Petter Segelman Lindqvist will present Isofol
Isofol presents at several upcoming investor meetings Read More »
GOTHENBURG, Sweden, November 12, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company’s interim report for January–September 2024 is now available, in Swedish, on the company’s website, www.isofolmedical.com. The information in the press release is intended for investors. Third quarter, July–September 2024 Net revenue amounted to kSEK 0 (0) and
Isofol Medical AB (publ) publishes interim report, January–September 2024 Read More »
GOTHENBURG, SWEDEN, October 23, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), today announces that a Late Breaking Abstract concerning the drug candidate arfolitixorin is presented as a poster at ENA 2024 in Barcelona, Spain, during October 23-25th 2024. The poster describes a dose-dependent cytotoxic effect and increased activity of arfolitixorin at higher doses
A Late Breaking Abstract concerning arfolitixorin will be presented at ENA 2024 today Read More »
GOTHENBURG, Sweden, September 12, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), today announces that the company has terminated the liquidity guarantee agreement with Pareto Securities. The agreement expires on September 13, 2024. The information in the press release is intended for investors. The purpose of a liquidity guarantee agreement is to improve share
Isofol terminates liquidity guarantee agreement Read More »
GOTHENBURG, Sweden, May 8, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company’s interim report for January–March 2024 is now available, in Swedish, on the company’s website, www.isofolmedical.com. The information in the press release is intended for investors. First quarter, January–March 2024 Net revenue amounted to kSEK 0 (721) and
Isofol Medical AB (publ) publishes interim report, January–March 2024 Read More »
GOTHENBURG, Sweden, March 19, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), (”Isofol”), today announces that the company’s collaboration partner, the Japanese pharmaceutical company Solasia Pharma K.K. (“Solasia”), has confirmed its continued strong commitment in the development of arfolitixorin. Solasia will contribute with its expertise and participate in defining the detailed design of the
